Literature DB >> 1952426

Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro.

C J Corrigan1, P H Brown, N C Barnes, S J Szefler, J J Tsai, A J Frew, A B Kay.   

Abstract

A total of 37 chronic, severe, nonsmoking asthmatic patients with documented reversible airways obstruction were classified as glucocorticoid-sensitive or -resistant on the basis of changes in FEV1, FVC, and peak expiratory flow (PEF) after oral prednisolone. The resistant patients showed no significant improvements in airflow limitation. Phytohemagglutinin (PHA)-induced proliferation of peripheral blood T lymphocytes from the sensitive but not the resistant asthmatic patients was significantly (p less than 0.01) inhibited by dexamethasone (10(-7) mol/L), reflecting a shift of the dose-response curve. When all the asthmatic patients were analyzed together, there was a significant correlation between the degree of sensitivity of T cells to dexamethasone and the clinical responsiveness to prednisolone (p less than 0.01). No differences were observed between six of the sensitive and resistant patients in the clearance of plasma prednisolone derived from orally administered prednisone. Peripheral blood mononuclear cell glucocorticoid receptors were also characterized in five sensitive and seven resistant patients. The numbers and binding affinities of these receptors could not account for the observed difference in the susceptibility of these cells to functional inhibition by dexamethasone in vitro. These results suggest that clinical glucocorticoid resistance in chronic asthma does not reflect abnormal glucocorticoid clearance but may be due at least partly to a relative insensitivity of T lymphocytes to glucocorticoids. This lack of sensitivity is unexplained but is not attributable to abnormalities of cellular glucocorticoid receptors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1952426     DOI: 10.1164/ajrccm/144.5.1016

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  46 in total

Review 1.  Glucocorticoid-resistant asthma.

Authors:  Tuck-Kay Loke; Ana R Sousa; Christopher J Corrigan; Tak H Lee
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

Review 2.  Recent advances in asthma.

Authors:  P J Barnes; T H Lee
Journal:  Postgrad Med J       Date:  1992-12       Impact factor: 2.401

3.  Effects of corticosteroids in acute severe asthma.

Authors:  N C Barnes
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

4.  Airway inflammation in children with difficult asthma: relationships with airflow limitation and persistent symptoms.

Authors:  D N R Payne; Y Qiu; J Zhu; L Peachey; M Scallan; A Bush; P K Jeffery
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

Review 5.  Glucocorticoid sensitivity in health and disease.

Authors:  Rogier A Quax; Laura Manenschijn; Jan W Koper; Johanna M Hazes; Steven W J Lamberts; Elisabeth F C van Rossum; Richard A Feelders
Journal:  Nat Rev Endocrinol       Date:  2013-10-01       Impact factor: 43.330

6.  Genetic mapping with multiple levels of phenotypic information reveals determinants of lymphocyte glucocorticoid sensitivity.

Authors:  Joseph C Maranville; Shaneen S Baxter; David B Witonsky; Meredith A Chase; Anna Di Rienzo
Journal:  Am J Hum Genet       Date:  2013-09-19       Impact factor: 11.025

7.  The NR3C1 Glucocorticoid Receptor Gene Polymorphisms May Modulate the TGF-beta mRNA Expression in Asthma Patients.

Authors:  Michał Panek; Tadeusz Pietras; Artur Fabijan; Jan Zioło; Łukasz Wieteska; Beata Małachowska; Wojciech Fendler; Janusz Szemraj; Piotr Kuna
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

Review 8.  Asthma that is unresponsive to usual care.

Authors:  Kenneth R Chapman; Andrew McIvor
Journal:  CMAJ       Date:  2009-10-13       Impact factor: 8.262

Review 9.  Clinical pharmacology of asthma. Implications for treatment.

Authors:  A J Frew; S T Holgate
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 10.  Combining genetic and nongenetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases.

Authors:  Joseph C Maranville; Anna Di Rienzo
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.